Fosun Pharmaceuticals (02196): Ketoprofen patch approved for clinical trial

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. Recently, the company's holding subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd. (“Zhaohui Pharmaceutical”) received approval from the State Drug Administration to conduct clinical trials with ketoprofen patches. Zhaohui Pharmaceutical plans to conduct phase III clinical trials of this drug in China when conditions are met. This drug is a chemical drug; it is mainly used for (1) analgesia and anti-inflammatory for the following diseases and symptoms: low back pain (myofascial pain syndrome, degenerative changes in the spine, disc disease, and lower back sprains), osteoarthritis, periodontitis, tendon sheath inflammation, lateral epicondylitis (tennis elbow), muscle pain, swelling and pain caused by trauma, and (2) local analgesia of rheumatoid arthritis.